Biohaven Ltd. (BHVN)
Health Care ยท Pharmaceutical Preparations
Biohaven Ltd. (BHVN) is listed on the New York Stock Exchange, where its shares have traded since September 23, 2022. SentiSense covers Biohaven Ltd. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Vlad Coric is its chief executive officer. The company reports 274 employees, and its corporate website is www.biohaven.com.
About Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 286 institutions reported holding BHVN, with 143.4 million shares worth $2.1 billion in aggregate. The largest reported holders were BlackRock, Suvretta Capital Management and Stifel Financial. Of the 5 largest reported holders, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
More on BHVN
- BHVN sentiment: whether news and social coverage of Biohaven Ltd. leans bullish or bearish, and the stories driving it.
- BHVN ownership: all 286 reporting institutions, plus insider and congressional trades.
- BHVN financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for Biohaven Ltd.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Biohaven Ltd. do?
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology.
What sector is BHVN in?
SentiSense classifies Biohaven Ltd. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does BHVN stock trade?
Biohaven Ltd. (BHVN) is listed on the New York Stock Exchange, where its shares have traded since September 23, 2022.
Who is the CEO of Biohaven Ltd.?
Vlad Coric is the chief executive officer of Biohaven Ltd..